BTIG’s Ryan Zimmerman now spotlights 18% in return potential for VCEL shares on back of an impressive fourth quarter performance.
Biopharmaceutical company Vericel Corp (NASDAQ:VCEL) reported record revenues and improved net income for the 2017 fourth quarter and full year, sending shares rising nearly 8% in …
Highlights from investor meetings with Vericel management.
Shares of Vericel Corp (NASDAQ:VCEL) are soaring nealy 67% as of 8:30 a.m.